Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00829049 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris
A Phase 4 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 4
- Development phase
- 165
- Enrollment target
NCT00829049: Clinical Trial Phase 4 study, sponsored by Allergan.
NCT00829049 is a Phase 4 study that was terminated before completion, run by Allergan. The registered enrollment target is 165 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00829049, a Phase 4 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 165 participants
- Enrollment target
Study Summary
Comparison of the safety and efficacy of Tazarotene Cream 0.1% compared with Adapalene Gel 0.3% in treating moderate to severe facial acne vulgaris
Primary Outcome
Median percent change from baseline in the non-inflammatory lesion counts (open and closed comedones) at Week 12. Comedones are small bumps on the skin (lesions) caused by acne and found at the opening of a skin pore. Open comedones (also known as blackheads) have a microscopic opening to the skin surface, while closed comedones (also known as whiteheads or pimples) lack the opening to the skin. A negative number change from baseline indicates a reduction in lesion counts(improvement).
Interventions
- DRUG Adapalene
- DRUG Tazarotene Cream 0.1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-10 |
| Phase | Phase 4 |
Why NCT00829049 stopped before completion
NCT00829049 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which Adapalene is the first listed.
NCT00829049 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00829049 about?
NCT00829049 is a clinical study titled "Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris". Comparison of the safety and efficacy of Tazarotene Cream 0.1% compared with Adapalene Gel 0.3% in treating moderate to severe facial acne vulgaris
What is the current status of trial NCT00829049?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 165 participants. The study started on 2007-10. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00829049?
The interventions under investigation include: Adapalene (DRUG), Tazarotene Cream 0.1% (DRUG).
Who is sponsoring clinical trial NCT00829049?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00829049's enrollment target sits among peer trials
165 492nd of 2000 higher than 1,505 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia